AG真人官方

STOCK TITAN

[8-K] FOXO Technologies Inc. Reports Material Event

Filing Impact
(High)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

FOXO Technologies Inc. (NYSE American: FOXO) filed an 8-K (Item 7.01) on 6-Aug-2025 disclosing two M&A updates. The company has signed a non-binding agreement to acquire an assisted-living and memory-care facility in South Florida. In addition, management states it is in the advanced stages of negotiating a definitive agreement to purchase Vector Biosource, Inc., a transaction previously announced.

The filing furnishes, rather than files, a press release (Ex. 99.1); therefore the information is not subject to Section 18 liabilities and is excluded from incorporation by reference unless specifically included elsewhere. No purchase price, financing details, or closing timelines were provided. All statements are forward-looking and contingent on concluding definitive agreements; closing remains uncertain.

FOXO Technologies Inc. (NYSE American: FOXO) ha presentato un modulo 8-K (Voce 7.01) il 6 agosto 2025, comunicando due aggiornamenti sulle fusioni e acquisizioni. La societ脿 ha firmato un accordo non vincolante per acquisire una struttura di assistenza per anziani e cura della memoria nel Sud della Florida. Inoltre, il management dichiara di essere nelle fasi avanzate della negoziazione di un accordo definitivo per l'acquisto di Vector Biosource, Inc., una transazione gi脿 annunciata in precedenza.

La comunicazione fornisce, anzich茅 depositare, un comunicato stampa (Ex. 99.1); pertanto, le informazioni non sono soggette alle responsabilit脿 della Sezione 18 e sono escluse dall'incorporazione per riferimento, salvo diversa indicazione. Non sono stati forniti dettagli sul prezzo di acquisto, finanziamenti o tempistiche di chiusura. Tutte le dichiarazioni sono proiettate al futuro e dipendono dalla conclusione degli accordi definitivi; la chiusura rimane incerta.

FOXO Technologies Inc. (NYSE American: FOXO) present贸 un formulario 8-K (Punto 7.01) el 6 de agosto de 2025, revelando dos actualizaciones sobre fusiones y adquisiciones. La empresa ha firmado un acuerdo no vinculante para adquirir una residencia asistida y centro de cuidado de memoria en el sur de Florida. Adem谩s, la direcci贸n afirma estar en las etapas avanzadas de negociaci贸n de un acuerdo definitivo para comprar Vector Biosource, Inc., una transacci贸n previamente anunciada.

La presentaci贸n proporciona, en lugar de presentar formalmente, un comunicado de prensa (Ex. 99.1); por lo tanto, la informaci贸n no est谩 sujeta a las responsabilidades de la Secci贸n 18 y queda excluida de la incorporaci贸n por referencia, salvo que se incluya espec铆ficamente en otro lugar. No se proporcionaron detalles sobre el precio de compra, financiamiento o plazos de cierre. Todas las declaraciones son prospectivas y dependen de la conclusi贸n de acuerdos definitivos; el cierre sigue siendo incierto.

FOXO Technologies Inc. (NYSE American: FOXO)電� 2025雲� 8鞗� 6鞚� 8-K 靹滊(Item 7.01)毳� 鞝滌稖頃橂┌ 霊� 瓯挫潣 鞚胳垬頃╇硲 鞐呺嵃鞚错姼毳� 瓿店皽頄堨姷雼堧嫟. 须岇偓电� 頂岆毽嫟 雮秬鞐� 鞙勳箻頃� 歆鞗� 欤柬儩 氚� 旮办柕 旃橂 鞁滌劋 鞚胳垬毳� 鞙勴暅 甑啀霠� 鞐嗠姅 瓿勳暯鞚� 觳搓舶頄堨姷雼堧嫟. 霕愴暅 瓴届榿歆勳潃 鞚挫爠鞐� 氚滍憸霅� 瓯半灅鞚� Vector Biosource, Inc. 鞚胳垬毳� 鞙勴暅 頇曥爼 瓿勳暯 順戩儊 雼硠鞐� 鞛堧嫟瓿� 氚濏様鞀惦媹雼�.

鞚措矆 鞝滌稖 靹滊電� 瓿奠嫕 鞝滌稖鞚� 鞎勲媽 氤措弰 鞛愲(Ex. 99.1)毳� 鞝滉车頃橂姅 瓴冹溂搿�, 鞚挫棎 霐半澕 鞝曤炒電� 靹轨厴 18 毂呾瀯 雽靸侅澊 鞎勲媹氅� 氤勲弰搿� 氇呾嫓霅橃 鞎婋姅 頃� 彀胳“ 韱淀暕鞐愳劀 鞝滌櫢霅╇媹雼�. 鞚胳垬 臧瓴�, 鞛愱笀 臁半嫭 靹鸽秬 靷暛, 毵堦皭 鞚检爼鞚 鞝滉车霅橃 鞎婌晿鞀惦媹雼�. 氇摖 歆勳垹鞚 氙鸽灅 鞓堨浮鞝侅澊氅� 頇曥爼 瓿勳暯 觳搓舶鞐� 雼牑 鞛堨溂氅�, 毵堦皭 鞁滌爯鞚 攵堩檿鞁ろ暕雼堧嫟.

FOXO Technologies Inc. (NYSE American : FOXO) a d茅pos茅 un 8-K (point 7.01) le 6 ao没t 2025, divulguant deux mises 脿 jour sur les fusions et acquisitions. La soci茅t茅 a sign茅 un accord non contraignant pour acqu茅rir une r茅sidence assist茅e et un centre de soins pour la m茅moire dans le sud de la Floride. De plus, la direction indique 锚tre dans les 茅tapes avanc茅es de n茅gociation d'un accord d茅finitif pour l'achat de Vector Biosource, Inc., une transaction annonc茅e pr茅c茅demment.

Le d茅p么t fournit, sans le d茅poser formellement, un communiqu茅 de presse (Ex. 99.1) ; par cons茅quent, l'information n'est pas soumise aux responsabilit茅s de la Section 18 et est exclue de l'incorporation par r茅f茅rence, sauf inclusion sp茅cifique ailleurs. Aucun d茅tail sur le prix d'achat, le financement ou le calendrier de cl么ture n'a 茅t茅 communiqu茅. Toutes les d茅clarations sont prospectives et conditionn茅es 脿 la conclusion d'accords d茅finitifs ; la cl么ture reste incertaine.

FOXO Technologies Inc. (NYSE American: FOXO) reichte am 6. August 2025 ein 8-K (Punkt 7.01) ein und gab zwei Updates zu Fusionen und 脺bernahmen bekannt. Das Unternehmen hat eine unverbindliche Vereinbarung zum Erwerb einer betreuten Wohn- und Ged盲chtnispflegeeinrichtung in S眉dflorida unterzeichnet. Zudem erkl盲rt das Management, sich in fortgeschrittenen Verhandlungen 眉ber einen endg眉ltigen Kaufvertrag f眉r Vector Biosource, Inc. zu befinden, eine bereits zuvor angek眉ndigte Transaktion.

Die Einreichung stellt eine Pressemitteilung (Ex. 99.1) bereit, reicht diese jedoch nicht ein; daher unterliegt die Information nicht den Haftungsbestimmungen gem盲脽 Abschnitt 18 und ist von der Einbeziehung durch Verweis ausgeschlossen, sofern nicht anderweitig ausdr眉cklich angegeben. Angaben zum Kaufpreis, zur Finanzierung oder zum Abschlusszeitpunkt wurden nicht gemacht. Alle Aussagen sind zukunftsgerichtet und abh盲ngig vom Abschluss endg眉ltiger Vereinbarungen; der Abschluss ist ungewiss.

Positive
  • Strategic expansion: Intention to enter senior-care market and acquire Vector Biosource broadens revenue opportunities.
  • Advanced negotiations: Management indicates definitive Vector Biosource agreement is "at an advanced stage," suggesting momentum toward closing.
Negative
  • Non-binding status: Current agreements are preliminary; transactions may not materialize.
  • No financial disclosure: Filing omits purchase price, funding sources, or expected financial impact, limiting visibility.

Insights

TL;DR: Non-binding deals hint at strategic pivot, but lack terms and certainty鈥攊nvestor impact currently neutral.

The announcement reveals intent to broaden FOXO鈥檚 footprint into senior housing and bolster biotech capabilities via Vector Biosource. While strategic diversification can unlock new revenue streams, the agreements are not definitive, contain no financial metrics, and could fail to close. Without valuation, funding structure, or synergies quantified, it is premature to model earnings accretion. I view near-term impact as neutral; materiality depends on future definitive terms.

TL;DR: Assisted-living target fits ageing-demographic trend, but execution risk high until deal terms emerge.

Entering senior-care operations could reposition FOXO from a pure-play tech company toward healthcare services, tapping stable occupancy-driven cash flows. Yet operational know-how, regulatory compliance, and capital intensity are significant hurdles. Investors should watch for purchase price relative to EBITDA, funding mix (debt vs. equity), and integration plans before reassessing valuation.

FOXO Technologies Inc. (NYSE American: FOXO) ha presentato un modulo 8-K (Voce 7.01) il 6 agosto 2025, comunicando due aggiornamenti sulle fusioni e acquisizioni. La societ脿 ha firmato un accordo non vincolante per acquisire una struttura di assistenza per anziani e cura della memoria nel Sud della Florida. Inoltre, il management dichiara di essere nelle fasi avanzate della negoziazione di un accordo definitivo per l'acquisto di Vector Biosource, Inc., una transazione gi脿 annunciata in precedenza.

La comunicazione fornisce, anzich茅 depositare, un comunicato stampa (Ex. 99.1); pertanto, le informazioni non sono soggette alle responsabilit脿 della Sezione 18 e sono escluse dall'incorporazione per riferimento, salvo diversa indicazione. Non sono stati forniti dettagli sul prezzo di acquisto, finanziamenti o tempistiche di chiusura. Tutte le dichiarazioni sono proiettate al futuro e dipendono dalla conclusione degli accordi definitivi; la chiusura rimane incerta.

FOXO Technologies Inc. (NYSE American: FOXO) present贸 un formulario 8-K (Punto 7.01) el 6 de agosto de 2025, revelando dos actualizaciones sobre fusiones y adquisiciones. La empresa ha firmado un acuerdo no vinculante para adquirir una residencia asistida y centro de cuidado de memoria en el sur de Florida. Adem谩s, la direcci贸n afirma estar en las etapas avanzadas de negociaci贸n de un acuerdo definitivo para comprar Vector Biosource, Inc., una transacci贸n previamente anunciada.

La presentaci贸n proporciona, en lugar de presentar formalmente, un comunicado de prensa (Ex. 99.1); por lo tanto, la informaci贸n no est谩 sujeta a las responsabilidades de la Secci贸n 18 y queda excluida de la incorporaci贸n por referencia, salvo que se incluya espec铆ficamente en otro lugar. No se proporcionaron detalles sobre el precio de compra, financiamiento o plazos de cierre. Todas las declaraciones son prospectivas y dependen de la conclusi贸n de acuerdos definitivos; el cierre sigue siendo incierto.

FOXO Technologies Inc. (NYSE American: FOXO)電� 2025雲� 8鞗� 6鞚� 8-K 靹滊(Item 7.01)毳� 鞝滌稖頃橂┌ 霊� 瓯挫潣 鞚胳垬頃╇硲 鞐呺嵃鞚错姼毳� 瓿店皽頄堨姷雼堧嫟. 须岇偓电� 頂岆毽嫟 雮秬鞐� 鞙勳箻頃� 歆鞗� 欤柬儩 氚� 旮办柕 旃橂 鞁滌劋 鞚胳垬毳� 鞙勴暅 甑啀霠� 鞐嗠姅 瓿勳暯鞚� 觳搓舶頄堨姷雼堧嫟. 霕愴暅 瓴届榿歆勳潃 鞚挫爠鞐� 氚滍憸霅� 瓯半灅鞚� Vector Biosource, Inc. 鞚胳垬毳� 鞙勴暅 頇曥爼 瓿勳暯 順戩儊 雼硠鞐� 鞛堧嫟瓿� 氚濏様鞀惦媹雼�.

鞚措矆 鞝滌稖 靹滊電� 瓿奠嫕 鞝滌稖鞚� 鞎勲媽 氤措弰 鞛愲(Ex. 99.1)毳� 鞝滉车頃橂姅 瓴冹溂搿�, 鞚挫棎 霐半澕 鞝曤炒電� 靹轨厴 18 毂呾瀯 雽靸侅澊 鞎勲媹氅� 氤勲弰搿� 氇呾嫓霅橃 鞎婋姅 頃� 彀胳“ 韱淀暕鞐愳劀 鞝滌櫢霅╇媹雼�. 鞚胳垬 臧瓴�, 鞛愱笀 臁半嫭 靹鸽秬 靷暛, 毵堦皭 鞚检爼鞚 鞝滉车霅橃 鞎婌晿鞀惦媹雼�. 氇摖 歆勳垹鞚 氙鸽灅 鞓堨浮鞝侅澊氅� 頇曥爼 瓿勳暯 觳搓舶鞐� 雼牑 鞛堨溂氅�, 毵堦皭 鞁滌爯鞚 攵堩檿鞁ろ暕雼堧嫟.

FOXO Technologies Inc. (NYSE American : FOXO) a d茅pos茅 un 8-K (point 7.01) le 6 ao没t 2025, divulguant deux mises 脿 jour sur les fusions et acquisitions. La soci茅t茅 a sign茅 un accord non contraignant pour acqu茅rir une r茅sidence assist茅e et un centre de soins pour la m茅moire dans le sud de la Floride. De plus, la direction indique 锚tre dans les 茅tapes avanc茅es de n茅gociation d'un accord d茅finitif pour l'achat de Vector Biosource, Inc., une transaction annonc茅e pr茅c茅demment.

Le d茅p么t fournit, sans le d茅poser formellement, un communiqu茅 de presse (Ex. 99.1) ; par cons茅quent, l'information n'est pas soumise aux responsabilit茅s de la Section 18 et est exclue de l'incorporation par r茅f茅rence, sauf inclusion sp茅cifique ailleurs. Aucun d茅tail sur le prix d'achat, le financement ou le calendrier de cl么ture n'a 茅t茅 communiqu茅. Toutes les d茅clarations sont prospectives et conditionn茅es 脿 la conclusion d'accords d茅finitifs ; la cl么ture reste incertaine.

FOXO Technologies Inc. (NYSE American: FOXO) reichte am 6. August 2025 ein 8-K (Punkt 7.01) ein und gab zwei Updates zu Fusionen und 脺bernahmen bekannt. Das Unternehmen hat eine unverbindliche Vereinbarung zum Erwerb einer betreuten Wohn- und Ged盲chtnispflegeeinrichtung in S眉dflorida unterzeichnet. Zudem erkl盲rt das Management, sich in fortgeschrittenen Verhandlungen 眉ber einen endg眉ltigen Kaufvertrag f眉r Vector Biosource, Inc. zu befinden, eine bereits zuvor angek眉ndigte Transaktion.

Die Einreichung stellt eine Pressemitteilung (Ex. 99.1) bereit, reicht diese jedoch nicht ein; daher unterliegt die Information nicht den Haftungsbestimmungen gem盲脽 Abschnitt 18 und ist von der Einbeziehung durch Verweis ausgeschlossen, sofern nicht anderweitig ausdr眉cklich angegeben. Angaben zum Kaufpreis, zur Finanzierung oder zum Abschlusszeitpunkt wurden nicht gemacht. Alle Aussagen sind zukunftsgerichtet und abh盲ngig vom Abschluss endg眉ltiger Vereinbarungen; der Abschluss ist ungewiss.

false 0001812360 0001812360 2025-08-06 2025-08-06 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date Earliest Event Reported): August 6, 2025

 

FOXO TECHNOLOGIES INC.

(Exact name of registrant as specified in its charter)

 

Delaware   001-39783   85-1050265

(State or Other Jurisdiction

of Incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

 

477 South Rosemary Avenue
Suite 224
West Palm Beach, FL
  33401
(Address of Principal Executive Offices)   (Zip Code)

 

(612) 800-0059

(Registrant’s telephone number, including area code)

 

 

(Former name or former address, if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Class A Common Stock, par value $0.0001   FOXO   NYSE American

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

 

 

 

 

 

Item 7.01 Regulation FD Disclosure.

 

On August 6, 2025, FOXO Technologies Inc., a Delaware corporation (the “Company”), issued a press release which announced that it has executed a non-binding acquisition agreement to acquire an assisted living and memory care facility in South Florida and it expects to shortly confirm a definitive agreement that is at an advanced stage of completion for the acquisition of Vector Biosource, Inc., which was previously announced. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

 

The information under this Item 7.01, including Exhibit 99.1 hereto, is being furnished herewith and shall not be deemed “filed” for the purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing. Furthermore, the furnishing of information under Item 7.01 of this Current Report on Form 8-K is not intended to constitute a determination by the Company that the information contained herein, including the exhibit hereto, is material or that the dissemination of such information is required by Regulation FD.

 

Cautionary Statement Regarding Forward-Looking Statements

 

This Current Report on Form 8-K contains “forward-looking statements.” Any statements contained in this Current Report on Form 8-K that do not describe historical facts may constitute forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “if,” “may,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negative of these terms or other comparable terminology. These forward-looking statements are based on information currently available to the Company’s management as well as estimates and assumptions made by its management and are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the statements. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, which may cause the Company’s or its industry’s actual results, levels of activity or performance to be materially different from any future results, levels of activity or performance expressed or implied by these forward-looking statements. These forward-looking statements are made as of the date of this Current Report on Form 8-K, and the Company does not undertake an obligation to update these forward-looking statements after such date.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit

Number

  Description of Exhibit
99.1   Press Release Dated August 6, 2025
104   Cover Page Interactive Data File (formatted in Inline XBRL)

 

2

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  FOXO Technologies Inc.
     
Date: August 6, 2025 By: /s/ Seamus Lagan
  Name: Seamus Lagan
  Title: Chief Executive Officer

 

3

 

FAQ

What did FOXO (FOXO) announce in its 8-K dated August 6, 2025?

The company disclosed a non-binding pact to buy a South Florida assisted-living facility and progress toward a definitive deal to acquire Vector Biosource.

Are the FOXO acquisitions definitive?

No. The assisted-living agreement is non-binding and the Vector Biosource deal is still being finalized.

Did FOXO reveal purchase prices or financing terms?

No financial terms, timelines, or funding details were provided in the filing.

Is the 8-K information considered 鈥渇iled鈥� or 鈥渇urnished鈥�?

The Item 7.01 disclosure is furnished, not filed, meaning it is exempt from Section 18 liability.

What risks are highlighted by FOXO鈥檚 forward-looking statements?

Management notes that closing depends on various unknown risks and uncertainties that could cause actual results to differ materially.
FOXO TECHNOLOGIES

NYSE:FOXO

FOXO Rankings

FOXO Latest News

FOXO Latest SEC Filings

FOXO Stock Data

1.30M
5.24M
1.76%
0.45%
2.48%
Health Information Services
Services-commercial Physical & Biological Research
United States
WEST PALM BEACH